Zacks Research Issues Positive Forecast for TSE:BHC Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research raised their Q3 2024 earnings per share estimates for Bausch Health Companies in a report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.44 for the quarter, up from their previous estimate of $1.41. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $1.34 EPS, Q3 2026 earnings at $1.80 EPS and FY2026 earnings at $6.85 EPS.

A number of other research firms also recently commented on BHC. Evercore ISI raised Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Raymond James raised Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 10th.

Bausch Health Companies Price Performance

Shares of TSE BHC opened at C$11.18 on Wednesday. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. The company has a market cap of C$4.10 billion, a PE ratio of -6.39, a P/E/G ratio of 0.21 and a beta of 0.77. The business has a 50-day simple moving average of C$9.50 and a two-hundred day simple moving average of C$9.95. Bausch Health Companies has a fifty-two week low of C$5.45 and a fifty-two week high of C$15.43.

Bausch Health Companies (TSE:BHC) last posted its earnings results on Thursday, August 1st. The company reported C$1.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The company had revenue of C$3.29 billion for the quarter, compared to analyst estimates of C$3.20 billion.

Insider Activity at Bausch Health Companies

In other news, Senior Officer Seana Lynne Carson sold 13,370 shares of Bausch Health Companies stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total value of C$112,087.40. 11.28% of the stock is currently owned by company insiders.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.